H

ello, everyone, and how are you today? We are doing just fine, thank you, especially as we are helped along by a bright, shiny sun enveloping the serene Pharmalot campus. Our shortest person has left for the local schoolhouse and the official mascots are sunning themselves in the parlor. As for us, we are as busy as ever, foraging for interesting items. Speaking of which, here are a few. Hope you have a lovely day and do keep in touch …

Hanmi Pharmaceutical belatedly reported a fatal side effect in a patient during clinical trials of its lung cancer drug Olita Tab, the Korea Herald tells us. The Board of Audit and Inspection of Korea said the drug maker broke two medical laws regarding the monitoring and reporting of its clinical trials. The board had opened an investigation after some lawmakers charged Hanmi of intentionally delaying reporting to win approval for the drug.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy